EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Case Report: Two cases of primary malignant melanoma of the female genital tract and literature review

Qi Li, Jia Zeng, Xidie Li, Meiyuan Huang, Yuqing Wu, Jinjin Wang, Huan Chen

Frontiers in Immunology · 31.03.2026 · 17

DOI: 10.3389/fimmu.2026.1797752 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Immunology, online erschienen am 31.03.2026. Verfasst von Qi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China. Hauptthemen laut MEDLINE: Melanoma, Uterine Cervical Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary malignant melanoma of the cervix (PMMC) is an exceptionally rare and aggressive malignancy with a poor prognosis. Due to its rarity, there are no standardized treatment guidelines. This case report presents two patients with PMMC, contributing to the literature through a novel treatment approach and literature review. Both patients presented with vaginal bleeding: one postmenopausal without obvious cervical pigmentation, the other premenopausal with a brown, friable cervical mass. Histopathology confirmed PMMC in both. The first patient underwent radical surgery without adjuvant therapy and died from recurrence 36 months later. The second patient received radical surgery, adjuvant chemotherapy, and bevacizumab maintenance, followed by a combination of carboplatin, dacarbazine, and Tislelizumab for pulmonary metastases, achieving significant tumor regression after two cycles. A review of nine reported cases treated with PD-1/PD-L1 inhibitors revealed that radical surgery was performed in 90% of patients, yet 80% did not receive chemotherapy or radiotherapy, and most (80%) still experienced disease progression with immunotherapy, underscoring its limited efficacy. PD-L1 expression, assessed in only three cases (all negative), did not reliably predict response. In conclusion, PMMC remains a formidable clinical challenge with high recurrence rates despite surgery. Response to immune checkpoint inhibitors is inconsistent, but multimodal strategies integrating surgery, chemotherapy, anti-angiogenic agents, and immunotherapy may offer clinical benefit and warrant further investigation to improve outcomes in this aggressive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaUterine Cervical NeoplasmsHumansFemaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsFatal OutcomeBevacizumabAdultAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

PD-L1bevacizumabcase reportimmunotherapyprimary cervical malignant melanomatislelizumab

Substanzen

BevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Department of Pathology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Department of Obstetrics and Gynecology, Hunan Provincial Maternal and Child Health Hospital, Changsha, Hunan, China.

Zitieren

APA

Li, Q., Zeng, J., Li, X., Huang, M., Wu, Y., Wang, J., & Chen, H. (2026). Case Report: Two cases of primary malignant melanoma of the female genital tract and literature review. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1797752

Vancouver

Li Q, Zeng J, Li X, Huang M, Wu Y, Wang J, et al. Case Report: Two cases of primary malignant melanoma of the female genital tract and literature review. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1797752

BibTeX
@article{Li2026,
  author = {Li, Qi and Zeng, Jia and Li, Xidie and Huang, Meiyuan and Wu, Yuqing and Wang, Jinjin and Chen, Huan},
  title = {Case Report: Two cases of primary malignant melanoma of the female genital tract and literature review},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1797752}
}
Kostenlos starten →